Prostate cancer: Enzalutamide impresses in European studies

@article{Payton2014ProstateCE,
  title={Prostate cancer: Enzalutamide impresses in European studies},
  author={Sarah Payton},
  journal={Nature Reviews Urology},
  year={2014},
  volume={11},
  pages={243-243}
}
  • S. Payton
  • Published 29 April 2014
  • Medicine
  • Nature Reviews Urology
Enzalutamide impresses in European studies Enzalutamide continues to extend its potential in men with prostate cancer. New data, published in the Lancet Oncology, suggest it might be a viable alternative to castration for patients with advanced disease, and subpopulation analysis of the PREVAIL study, presented at the European Association of Urology (EAU) annual meeting in Stockholm, confirms its benefit as first-line therapy for European patients with castration-resistant prostate cancer (CRPC… 
3 Citations

Prostate cancer: Enzalutamide PREVAILs

TLDR
Interim analysis of the PREVAIL trial demonstrates that enzalutamide not only significantly improves survival outcomes, but also delays the need for chemotherapy, reduces serum PSA levels and is associated with better health-related quality of life.

A Validated Stability Indicating RP-HPLC Method Development for Anticancer Drug Enzalutamide in Bulk and Pharmaceuticals

A reproducible stability-indicating Reverse Phase-HPLC technique for the quantification of Enzalutamide in in pharmaceuticals was developed and validated. Chromatography was done on Inertsil ODS-C18

Synthesis of 4,4′-substituted 2,2′-[ethane-1,2-diylbis(selanediyl)]bis(1H-imidazol-5(4H)-ones)

Synthesis of new bis(seleno-imidazolone) derivatives bearing the alkyl and aryl moieties at the N(1) atom of the five-membered ring was developed. Cytotoxicity of the synthesized compounds against